Good Therapeutics, a new Seattle biotech startup that aims to develop protein drugs that act only when needed, raised $11 million in an equity round, according to a new SEC filing.
The secretive startup is trying to “make safer, more effective drugs that act only when and where they are needed, limiting systemic toxicity without reducing therapeutic efficacy,” according to its website. Good said it is developing an algorithm that will design proteins for cancer therapies.
